Experimental Hormone Therapy May Speed Recovery for COVID Patientshttps://m.startribune.com/hormone-boost-could-be-covid-19-key/572944532/Dr. Tim Rich and the University of Minnesota’s Dr. David Ingbar had studied for years whether a common thyroid hormone (T3, triiodothyronine) could be repurposed for the treatment of acute respiratory distress syndrome (ARDS), an often fatal type of lung failure in COVID-19.Rich and Ingbar made a key discovery during the H1N1 pandemic of 2009, when families of those who died from influenza-related ARDS permitted autopsies. Rich found the victims’ lungs lacked T3, a thyroid hormone that would normally be detectable.
Ingbar said T3 reduces inflammation and coaxes epithelial cells in the lungs to absorb fluids — which is vital for patients with ARDS.
“A part of this acute lung injury with ARDS from COVID-19 is the lungs get leaky, and they tend to fill with fluid,” Ingbar said. “That makes it really hard to get oxygen in or carbon dioxide out.”
“There has been a lot of highly technical science to understand this biology, but the elegance now is in its simplicity,” said Rich, a pulmonologist. “This is not a designer drug. This is something we know the lung needs and uses.
ARDS stems from a variety of causes, including heat, physical trauma or inhaled substances.
Research showed that any such lung injury produces more of an enzyme that breaks down T3.“There’s a real local destruction of the hormone that explains why its concentration is so low,” Ingbar said.
Doctors administer the hormone directly to a patient’s lungs through a breathing tube. That is a novel part of this study, as sick people have received thyroid hormones for years, but never straight into their lungs in this manner.... “This is really a much faster recovery than we see with typical ARDS,” said Ingbar, noting that many survivors have lung scarring that can cause breathing problems for years and the need for supplemental oxygen.
“Any survival of ARDS, especially this COVID ARDS, is exciting, but it’s not enough to survive,” Rich said. “It’s to not have the morbidity of a compromised lung for the rest of your life.”
The U’s Center for Translational Medicine is working to produce a patented powder T3 formulation. That inhaled or nebulized form would be cheaper and easier to administer, meaning more patients could receive it if it proves safe and effective
https://en.m.wikipedia.org/wiki/Triiodothyronine